From GlobeNewswire: 2024-03-26 16:01:00

In the Phase 1 study of CAB-CTLA-4 (BA3071), dose-limiting toxicity (DLT) period cleared at 700 mg, with Phase 2 monotherapy data expected in 2Q 2024 and combination with pembrolizumab in 2H 2024. CAB-ROR2 (BA3021) Phase 2 melanoma and SCCHN trials fully enrolled, with data readouts expected in 2Q 2024.

CAB-AXL (BA3011) Phase 2 study in UPS on track for completion in April with FDA meeting anticipated in 2H 2024. CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 study progressing for full data readout in 2H 2024. Cash balance of $111.5 million expected to fund operations into 2H 2025.

BioAtla, Inc. announced positive financial results for Q4 and full year ended December 31, 2023. Progress includes clearance of DLT period in BA3071 study, advancement of CAB-ADC clinical trials, and plans for upcoming data readouts and potentially registrational trials. Management to host a conference call and webcast today at 4:30 PM Eastern Time.



Read more at GlobeNewswire:: BioAtla Reports Fourth Quarter and Full Year 2023 Financial